Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia.
about
Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevanceRapid detection of DNMT3A R882 mutations in hematologic malignancies using a novel bead-based suspension assay with BNA(NC) probesHigher HOPX expression is associated with distinct clinical and biological features and predicts poor prognosis in de novo acute myeloid leukemiaClinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations.DNMT3A in haematological malignancies.The N-terminal CEBPA mutant in acute myeloid leukemia impairs CXCR4 expressionDNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategiesClinical and prognostic implications of Roundabout 4 (robo4) in adult patients with acute myeloid leukemia.Integrated genomic profiling, therapy response, and survival in adult acute myelogenous leukemiaRole of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution.Lipidomic approach for stratification of acute myeloid leukemia patients.Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemiaMultiplexed automated digital quantification of fusion transcripts: comparative study with fluorescent in-situ hybridization (FISH) technique in acute leukemia patients.Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.Evaluation of DNMT3A genetic polymorphisms as outcome predictors in AML patients.A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice.Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors.Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.DNA methylation in normal and malignant hematopoiesis.BP1 overexpression is associated with adverse prognosis in de novo acute myeloid leukemia.Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemiaOverexpression of SOX4 correlates with poor prognosis of acute myeloid leukemia and is leukemogenic in zebrafishClinico-biological significance of suppressor of cytokine signaling 1 expression in acute myeloid leukemia.Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia.Outcomes of 1st Remission Induction Chemotherapy in Acute Myeloid Leukemia Cytogenetic Risk GroupsImage-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.Emerging molecular predictive and prognostic factors in acute myeloid leukemia.Overexpression of FLT3-ITD driven by spi-1 results in expanded myelopoiesis with leukemic phenotype in zebrafish.Dynamics of DNMT3A mutation and prognostic relevance in patients with primary myelodysplastic syndrome.Genetic alterations and their clinical implications in older patients with acute myeloid leukemia.GATA2 zinc finger 1 mutations are associated with distinct clinico-biological features and outcomes different from GATA2 zinc finger 2 mutations in adult acute myeloid leukemia
P2860
Q26776393-BC33597C-02EA-4C85-8EE6-AB6E46642845Q33734576-78A6EA8A-F9B2-4759-8F5C-E29595090379Q33746724-B9A637D4-22E9-4C0D-BA50-201D653B1900Q34340438-AFE25467-D1D5-4C1D-A869-04693FA176ECQ34463554-DE20D337-D7A4-4724-9885-FA3797730633Q34649120-1D30C345-73AA-4FEF-A6C9-A9473CAFD43AQ34661033-6F677A47-1D48-4801-9E5E-B300076A19E1Q35203340-E931BEEF-DCF1-43C0-AFC7-A064C60B6BE0Q35562821-45648254-9ADD-4E1B-BABB-322658F5A751Q35781605-B02CC9E3-7772-46F5-8838-C01D249393DCQ35921904-6F6C8DF1-34F2-4A3A-9617-2F97E793A792Q36282427-B821AAF4-A7C4-43F2-9956-53D8D90741A5Q36962514-93689CBD-0708-4534-990B-9817D9432290Q37258116-E5090B9C-DE7C-44FA-B8A0-E3782BA57E45Q37362603-2B446825-903C-4A57-8535-1F729D5192AAQ37645063-8A92E0B7-5F72-4219-8340-D1E9A3B7982CQ37648114-17ED117B-7A93-4D17-9584-87E44AAFB0B4Q38263126-066F0562-79C8-40B7-A133-8A5450116559Q38703904-7A1A20C4-0204-48A4-B413-EF14859A0A53Q38760713-7337B6D5-C1F5-49C5-9F5E-A04D22B49174Q38839165-B2C0B99E-A51E-4645-8745-0B9DED2803A1Q39063991-837E5525-A744-4BDF-8483-798C91486458Q41177054-A1700429-A739-4174-9A54-5039BA993BE5Q41316658-578BC360-1BEF-41C5-B3B9-4F5691FD1EF3Q41818692-CC5EFC2B-B808-4400-9267-C4CFDF21452FQ41983363-C1B69DF6-7F4A-4FD0-8703-48F9B60E7B80Q47156715-E40E422A-5D41-4D36-8C1B-2A62AAD42A82Q47670541-AE01F50E-ED48-453A-BF0D-6B1B9A3A9894Q53087769-4D7913A6-1664-4C50-88F8-9CACFC759E2BQ55009819-FDBDDBB9-27E8-489B-8C99-C124599C782EQ55025720-3B57EA53-2390-401E-B6F8-A5C6EED98792Q58781139-37CF4A1F-8A59-4199-9B31-B73B82E7CE0E
P2860
Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Integration of cytogenetic and ...... non-M3 acute myeloid leukemia.
@en
Integration of cytogenetic and ...... non-M3 acute myeloid leukemia.
@nl
type
label
Integration of cytogenetic and ...... non-M3 acute myeloid leukemia.
@en
Integration of cytogenetic and ...... non-M3 acute myeloid leukemia.
@nl
prefLabel
Integration of cytogenetic and ...... non-M3 acute myeloid leukemia.
@en
Integration of cytogenetic and ...... non-M3 acute myeloid leukemia.
@nl
P2093
P2860
P50
P356
P1433
P1476
Integration of cytogenetic and ...... non-M3 acute myeloid leukemia
@en
P2093
P2860
P2888
P356
10.1038/LEU.2013.236
P577
2013-08-09T00:00:00Z